Florence Herschke

Beerse, VLG 2340, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.

Optimal preclinical models for human dose projection of SARS-CoV-2 small molecule direct-acting antivirals.

Journal: Antiviral research

Published: September 03, 2025

Insights in the RSV L polymerase function and structure.

Insights in the RSV L polymerase function and structure.

Journal: Antiviral research

Published: January 15, 2025

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.

Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.

Journal: PLoS medicine

Published: January 08, 2025

Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors.

Discovery of gem-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors.

Journal: Journal of medicinal chemistry

Published: August 06, 2024

Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections.

Spiro-Azetidine Oxindoles as Long-Acting Injectables for Pre-Exposure Prophylaxis against Respiratory Syncytial Virus Infections.

Journal: Journal of medicinal chemistry

Published: June 27, 2024

Direct-acting antivirals for RSV treatment, a review.

Direct-acting antivirals for RSV treatment, a review.

Journal: Antiviral research

Published: April 19, 2024

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.

Journal: Antiviral research

Published: April 07, 2024

Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor.

Structural and mechanistic insights into the inhibition of respiratory syncytial virus polymerase by a non-nucleoside inhibitor.

Journal: Communications biology

Published: August 07, 2023

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.

A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults.

Journal: Antiviral therapy

Published: May 18, 2023

JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.

JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.

Journal: Antiviral research

Published: May 11, 2021

2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.

2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.

Journal: Journal of medicinal chemistry

Published: July 03, 2018

Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.

Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.

Journal: Bioorganic & medicinal chemistry letters

Published: March 09, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026